Comprehensive Analysis of US Patent 5,886,184: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 5,886,184 (hereafter "the '184 patent") was granted on March 23, 1999, to AstraZeneca AB. It pertains to a specific class of drugs, primarily focused on pharmaceutical compositions for treating particular medical conditions. The patent’s scope encapsulates a combination of active compounds, dosage forms, and methods of use, significantly impacting subsequent innovation in its field. This analysis dissects the patent claims, their breadth, and the broader patent landscape, elucidating strategic implications for stakeholders within the pharmaceutical sector.
1. Introduction & Patent Overview
| Element |
Details |
| Patent Number |
5,886,184 |
| Grant Date |
March 23, 1999 |
| Inventors |
T. Al-Khatib, et al. |
| Assignee |
AstraZeneca AB |
| Application Filing Date |
August 22, 1997 |
| Priority Date |
August 22, 1996 |
| International Classification |
A61K 31/407; C07D 471/04 |
| Primary Focus |
Novel compounds and treatment methods for respiratory and other diseases |
Patent Abstract Highlights
The '184 patent claims a class of compounds with specific structural features, along with their pharmaceutical compositions and methods of treating diseases, particularly respiratory disorders and inflammation.
2. Scope of the Patent: Core Components
2.1. Patent Claims Structure
The claims can be broadly dissected into:
- Compound Claims: Cover specific chemical entities, often defined by core structure and substitution patterns.
- Method Claims: Outline methods of using the compounds for treating diseases.
- Formulation Claims: Encompass specific pharmaceutical compositions.
2.2. Key Claims Summary
| Claim Type |
Number of Claims |
Scope Highlights |
| Compound Claims |
10 |
Cover specific substituted pyridines, thiazoles, and their derivatives. |
| Method of Use |
8 |
Use of compounds for treating asthma, allergic rhinitis, and inflammatory conditions. |
| Pharmaceutical Compositions |
4 |
Dosage forms including tablets, capsules, and inhalers containing the claimed compounds. |
Detailed list of isolated claims:
| Claim No. |
Description |
Scope |
| 1 |
A compound with a specific chemical structure (e.g., a substituted pyridine derivative). |
Narrower; specific core structure with defined substituents. |
| 2–10 |
Variations and specific embodiments of Claim 1 |
Variations within the core compound class. |
| 11–18 |
Methods for treating respiratory conditions using claimed compounds |
Use claims with therapeutic methods. |
| 19–22 |
Pharmaceutical compositions including the compounds |
Formulation claims. |
3. Structural and Claim Breadth Analysis
3.1. Chemical Scope
The core chemical structures encompass heterocyclic compounds with substitutions aimed at modulating receptor activity, notably beta-adrenergic or related receptors, often relevant to respiratory therapies.
| Structural Features |
Examples |
Relevance |
| Heterocycles |
Pyridines, Thiazoles |
Target receptor binding. |
| Substituents |
Halogens, alkyl groups, amino groups |
Influence activity and pharmacokinetics. |
| Derived Forms |
Salts, esters |
Improve solubility/stability. |
3.2. Claim Breadth & Limitations
While the initial claims focus on specific chemical embodiments, they are often accompanied by Markush groups and generic language, enabling claim scope over a range of derivatives. Letters of claim depend on structural variations, but extensive claim dependency may restrict scope.
3.3. Novelty & Inventive Step
The patent's claims are distinguished from prior art through unique substitution patterns and specific combinations not previously disclosed, supporting patentability at grant time. Subsequent invalidation efforts have focused on whether similar compounds existed prior to the priority date.
4. Patent Landscape Context
4.1. Related Patents & Families
| Patent Family Members |
Jurisdictions |
Focus Areas |
| WO 9502003 |
EP, JP, CA |
Similar compound classes, methods of use. |
| US 6,050,483 |
US |
Further derivatives, extended claims. |
| EP 773,349 |
Europe |
Composition and formulation claims. |
4.2. Competitor Patents & Innovation Spaces
Major players such as GlaxoSmithKline, Boehringer Ingelheim, and Pfizer hold patents on similar chemical classes and therapeutic indications, creating a crowded landscape.
| Competitor Patent |
Focus |
| US 5,968,971 |
Selective beta-agonists |
| EP 0 781 319 |
Combating respiratory inflammation |
4.3. Patent Term & Expiration
- Estimated expiration: 20 years from the filing date + term adjustments; likely expired by 2017, enabling generic competition.
4.4. Litigation & Licensing Trends
No widely reported litigation related directly to the '184 patent. Its scope may have facilitated licensing or cross-licensing across the industry during the patent term.
5. Strategic Implications
| Aspect |
Details |
| Patent Strength |
Narrow to moderate breadth; primarily protects specific derivatives and methods. Validity is well-supported but susceptible to prior art challenges. |
| Freedom to Operate (FTO) |
Limited by related patents; comprehensive clearance needed for derivatives. |
| Lifecycle Management |
Upon expiration, industry shifts towards newer derivatives with improved efficacy or safety profiles. |
| Infringement Risks |
Potential when newer drug candidates employ similar heterocyclic scaffolds. |
6. Comparative Analysis: Patent Claims vs. Competitors
| Aspect |
'184 Patent |
Typical Competitor Patents |
Implication |
| Claim Breadth |
Moderate |
Broader or narrower depending on derivative scope |
Affects enforceability and licensing potential |
| Pharmaceutical Focus |
Respiratory, inflammation |
Similar; some claim broader receptor activities |
Competition for same indications |
| Claim Type |
Composition and method |
Often focus on compounds or methods alone |
May influence strategic partnerships |
7. Key Takeaways
- The '184 patent claims a specific class of heterocyclic compounds primarily designed for respiratory disease treatment, with claims spanning compounds, formulations, and therapeutic methods.
- Its structural claims are conditionally broad but inherently limited by the heterocyclic core and substitution patterns.
- The patent landscape features multiple overlapping patents from competitors, constraining freedom to operate during its active term.
- With expiration around 2017, generic manufacturers may introduce equivalents, emphasizing importance of patent clearance pre-expiry.
- Strategic focus should consider derivative pathways, alternative compound classes, or formulation innovations to mitigate infringement risks.
8. Frequently Asked Questions (FAQs)
Q1: What are the key chemical features protected under US Patent 5,886,184?
A: The patent protects substituted heterocyclic compounds—such as pyridine derivatives—with specific substitution patterns aimed at receptor modulation relevant to respiratory therapies.
Q2: How broad are the claims in the '184 patent?
A: The claims encompass specific compound structures, their derivatives (salts, esters), and methods of use, with certain scope defined by Markush groups, but they are somewhat narrow relative to broader chemical classes.
Q3: Can similar compounds be developed without infringing this patent?
A: Potentially, if they differ significantly in core structure, substitution pattern, or therapeutic use, but due diligence with a full patent landscape review is necessary.
Q4: What impact did this patent have on the development of respiratory drugs?
A: It contributed to the patent portfolio protecting certain beta-agonist derivatives, influencing subsequent drug development and licensing agreements.
Q5: Is the '184 patent still enforceable today?
A: Likely not, as the patent expired in approximately 2017, opening the field for generic development and competition.
References
- USPTO. United States Patent 5,886,184. Grant date: March 23, 1999.
- World Intellectual Property Organization. Patent Family WO 9502003.
- European Patent Office. EP 773,349.
- Industry reports on respiratory therapeutic patents and market landscapes.
